SG151260A1 - 5-substituted-2-phenylamino-benzamides as mek inhibitors - Google Patents
5-substituted-2-phenylamino-benzamides as mek inhibitorsInfo
- Publication number
- SG151260A1 SG151260A1 SG200901715-3A SG2009017153A SG151260A1 SG 151260 A1 SG151260 A1 SG 151260A1 SG 2009017153 A SG2009017153 A SG 2009017153A SG 151260 A1 SG151260 A1 SG 151260A1
- Authority
- SG
- Singapore
- Prior art keywords
- substituted
- mek inhibitors
- benzamides
- phenylamino
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/04—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004218004 | 2004-07-26 | ||
JP2005072093 | 2005-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG151260A1 true SG151260A1 (en) | 2009-04-30 |
Family
ID=35786215
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200901865-6A SG151286A1 (en) | 2004-07-26 | 2005-07-26 | 5-substituted-2-phenylamino-benzamide as mek inhibitor |
SG200901715-3A SG151260A1 (en) | 2004-07-26 | 2005-07-26 | 5-substituted-2-phenylamino-benzamides as mek inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200901865-6A SG151286A1 (en) | 2004-07-26 | 2005-07-26 | 5-substituted-2-phenylamino-benzamide as mek inhibitor |
Country Status (27)
Country | Link |
---|---|
US (2) | US7745663B2 (ja) |
EP (1) | EP1780197B9 (ja) |
JP (1) | JP4090070B2 (ja) |
KR (1) | KR101153556B1 (ja) |
CN (1) | CN101124199B (ja) |
AT (1) | ATE485265T1 (ja) |
AU (1) | AU2005265769B2 (ja) |
BR (1) | BRPI0513750A (ja) |
CA (1) | CA2575232C (ja) |
CY (1) | CY1110969T1 (ja) |
DE (1) | DE602005024279D1 (ja) |
DK (1) | DK1780197T3 (ja) |
ES (1) | ES2354822T3 (ja) |
HK (1) | HK1116766A1 (ja) |
HR (1) | HRP20110006T1 (ja) |
IL (1) | IL179634A (ja) |
MX (1) | MX2007000736A (ja) |
MY (1) | MY144232A (ja) |
NO (1) | NO20071042L (ja) |
NZ (1) | NZ551812A (ja) |
PL (1) | PL1780197T3 (ja) |
PT (1) | PT1780197E (ja) |
RS (1) | RS51783B (ja) |
SG (2) | SG151286A1 (ja) |
SI (1) | SI1780197T1 (ja) |
TW (1) | TWI361066B (ja) |
WO (1) | WO2006011466A1 (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1674452A4 (en) * | 2003-09-19 | 2007-10-10 | Chugai Pharmaceutical Co Ltd | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR |
MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
CN110668988A (zh) | 2005-10-07 | 2020-01-10 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek抑制剂的吖丁啶 |
AU2007334402B2 (en) | 2006-12-14 | 2014-02-13 | Exelixis, Inc. | Methods of using MEK inhibitors |
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
JP5892612B2 (ja) * | 2009-10-13 | 2016-03-23 | アロメック セラピューティクス エルエルシーAllomek Therapeutics Llc | 疾患の処置に有用な新規のmek阻害剤 |
BR112012021411A2 (pt) | 2010-02-25 | 2017-04-18 | Dana Farber Cancer Inst Inc | mutações braf que conferem resistência a inibidores braf. |
EA030276B1 (ru) | 2010-03-09 | 2018-07-31 | Дана-Фарбер Кэнсер Инститьют, Инк. | Способы идентификации страдающих раком пациентов и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака |
US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
ES2575995T3 (es) * | 2010-08-05 | 2016-07-04 | Case Western Reserve University | Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal |
US20130123255A1 (en) * | 2011-11-10 | 2013-05-16 | Chugai Seiyaku Kabushiki Kaisha | Combination of a pi3k inhibitor and a mek inhibitor |
GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
NZ706723A (en) | 2012-10-12 | 2018-07-27 | Exelixis Inc | Novel process for making compounds for use in the treatment of cancer |
JP2016034901A (ja) * | 2012-11-26 | 2016-03-17 | 中外製薬株式会社 | 3,4−ジフルオロ−2−(2−フルオロ−4−ヨード−フェニルアミノ)−n−(2−ヒドロキシ−エトキシ)−5−(3−オキソ−[1,2]オキサジナン−2−イルメチル)−ベンズアミドの新規結晶形 |
JP2016034900A (ja) * | 2012-11-26 | 2016-03-17 | 中外製薬株式会社 | 5−置換−2−フェニルアミノ−ベンズアミド類の製造方法 |
EP3249054A1 (en) | 2012-12-20 | 2017-11-29 | Biomatrica, INC. | Formulations and methods for stabilizing pcr reagents |
ES2703208T3 (es) | 2013-02-27 | 2019-03-07 | Daiichi Sankyo Co Ltd | Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK |
US20160135446A1 (en) | 2013-06-13 | 2016-05-19 | Biomatrica, Inc. | Cell stabilization |
JP6661554B2 (ja) | 2014-06-10 | 2020-03-11 | バイオマトリカ,インク. | 周囲温度における血小板の安定化 |
CN104860869B (zh) * | 2015-04-03 | 2017-11-03 | 北京大学 | 具有mek激酶抑制功能的化合物及其制备方法与应用 |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
WO2017100212A1 (en) | 2015-12-08 | 2017-06-15 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
AR121078A1 (es) * | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
CA3174992A1 (en) * | 2020-03-02 | 2021-09-10 | Sironax Ltd. | Ferroptosis inhibitors - diarylamine para-acetamides |
US20230271932A1 (en) * | 2020-06-16 | 2023-08-31 | Dana-Farber Cancer Institute, Inc. | Small molecule covalent activators of ucp1 |
PE20231094A1 (es) | 2020-07-22 | 2023-07-18 | Chugai Pharmaceutical Co Ltd | Composicion que contiene un derivado de arilamida |
JPWO2022018875A1 (ja) | 2020-07-22 | 2022-01-27 | ||
WO2023003014A1 (ja) | 2021-07-21 | 2023-01-26 | 中外製薬株式会社 | アリールアミド誘導体の製造方法 |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
CN114672482B (zh) * | 2022-05-31 | 2022-08-30 | 上海百力格生物技术有限公司 | 核酸探针制备方法 |
WO2024002210A1 (zh) * | 2022-06-30 | 2024-01-04 | 上海喆邺生物科技有限公司 | 一种芳香酰胺类衍生物及其在抗肿瘤药物中的应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2967187A (en) | 1958-12-31 | 1961-01-03 | Standard Oil Co | Production of anthraquinone |
US4001420A (en) | 1968-12-12 | 1977-01-04 | Science Union Et Cie, Societe Francaise De Recherche Medical | Thiazolyl benzoic acid compounds |
GB1248070A (en) | 1968-12-16 | 1971-09-29 | Science Union & Cie | Thiazolyl-benzoic acid derivatives and process for preparing them |
BE790859A (fr) | 1971-11-02 | 1973-04-30 | Pfizer | Acides carboxamidobenzoiques comme agents hypolipemiques |
US4469885A (en) | 1983-05-09 | 1984-09-04 | G. D. Searle & Co. | Halogenated protease inhibitors |
US4501895A (en) | 1983-05-09 | 1985-02-26 | G.D. Searle & Co. | [Halo-4-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-phenyl]octadecan-ols and -ones |
ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
WO2000020390A1 (en) * | 1998-10-07 | 2000-04-13 | Georgetown University | Monomeric and dimeric heterocycles, and therapeutic uses thereof |
AU776788C (en) | 1998-12-16 | 2005-10-27 | Warner-Lambert Company | Treatment of arthritis with MEK inhibitors |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
OA11746A (en) | 1999-01-13 | 2005-05-13 | Warner Lambert Co | Benzoheterocycles and their use as MEK inhibitors. |
ATE309205T1 (de) | 1999-01-13 | 2005-11-15 | Warner Lambert Co | Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren |
AU5786000A (en) * | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
CA2403017A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
EP1339702A1 (en) | 2000-03-15 | 2003-09-03 | Warner-Lambert Company | 5-amide substituted diarylamines as mek inhibitors |
DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
AU2002366362A1 (en) | 2001-12-18 | 2003-06-30 | Bayer Aktiengesellschaft | 2-substituted pyrrolo(2.1-a)isoquinolines against cancer |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
EP1674452A4 (en) | 2003-09-19 | 2007-10-10 | Chugai Pharmaceutical Co Ltd | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR |
MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
CN101555016B (zh) | 2008-04-09 | 2011-06-08 | 清华大学 | 硅化镍纳米线的制备方法 |
-
2005
- 2005-07-25 MY MYPI20053404A patent/MY144232A/en unknown
- 2005-07-25 TW TW094125122A patent/TWI361066B/zh not_active IP Right Cessation
- 2005-07-26 EP EP05767184A patent/EP1780197B9/en active Active
- 2005-07-26 AT AT05767184T patent/ATE485265T1/de active
- 2005-07-26 RS RS20100467A patent/RS51783B/en unknown
- 2005-07-26 BR BRPI0513750-0A patent/BRPI0513750A/pt not_active IP Right Cessation
- 2005-07-26 JP JP2006529328A patent/JP4090070B2/ja not_active Expired - Fee Related
- 2005-07-26 MX MX2007000736A patent/MX2007000736A/es active IP Right Grant
- 2005-07-26 ES ES05767184T patent/ES2354822T3/es active Active
- 2005-07-26 SG SG200901865-6A patent/SG151286A1/en unknown
- 2005-07-26 PL PL05767184T patent/PL1780197T3/pl unknown
- 2005-07-26 WO PCT/JP2005/013620 patent/WO2006011466A1/ja active Application Filing
- 2005-07-26 NZ NZ551812A patent/NZ551812A/en not_active IP Right Cessation
- 2005-07-26 DK DK05767184.4T patent/DK1780197T3/da active
- 2005-07-26 PT PT05767184T patent/PT1780197E/pt unknown
- 2005-07-26 SI SI200531201T patent/SI1780197T1/sl unknown
- 2005-07-26 AU AU2005265769A patent/AU2005265769B2/en not_active Ceased
- 2005-07-26 DE DE602005024279T patent/DE602005024279D1/de active Active
- 2005-07-26 SG SG200901715-3A patent/SG151260A1/en unknown
- 2005-07-26 US US11/658,533 patent/US7745663B2/en not_active Expired - Fee Related
- 2005-07-26 CA CA2575232A patent/CA2575232C/en not_active Expired - Fee Related
- 2005-07-26 KR KR1020077003522A patent/KR101153556B1/ko not_active IP Right Cessation
- 2005-07-26 CN CN2005800252904A patent/CN101124199B/zh not_active Expired - Fee Related
-
2006
- 2006-11-27 IL IL179634A patent/IL179634A/en not_active IP Right Cessation
-
2007
- 2007-02-23 NO NO20071042A patent/NO20071042L/no not_active Application Discontinuation
-
2008
- 2008-07-02 HK HK08107296.8A patent/HK1116766A1/xx not_active IP Right Cessation
-
2010
- 2010-04-01 US US12/752,396 patent/US8575391B2/en not_active Expired - Fee Related
- 2010-12-03 CY CY20101101112T patent/CY1110969T1/el unknown
-
2011
- 2011-01-05 HR HR20110006T patent/HRP20110006T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG151260A1 (en) | 5-substituted-2-phenylamino-benzamides as mek inhibitors | |
MXPA05008172A (es) | Derivados de malonamida como inhibidores gamma-secretasa. | |
MXPA03010435A (es) | Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes. | |
NZ539841A (en) | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | |
TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
ATE365742T1 (de) | 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren | |
MX2009006756A (es) | Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv. | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
TW200745097A (en) | 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors | |
MX2007013624A (es) | Inhibidores de proteina cinasa. | |
ZA200408283B (en) | 7-aryl-3,9-diazabicyclo (3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardivascular or rental diseases | |
EP1689713A4 (en) | BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE | |
TW200745136A (en) | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives | |
EP2091328A4 (en) | SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE | |
EP1817312A4 (en) | MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
EA200800370A1 (ru) | Новая фармацевтическая лекарственная форма ингибитора фермента циклооксигеназы с модифицированным высвобождением | |
ATE507226T1 (de) | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung | |
MX2007006744A (es) | Derivados de hidantoina utiles como inhibidores de metaloproteinasa. | |
PL1685142T3 (pl) | Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera | |
ATE357453T1 (de) | Comt-inhibitoren | |
GB0314967D0 (en) | Piperazine derivatives | |
IL195016A0 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
EP2073635A4 (en) | MACROCYCLIC SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
MXPA05012369A (es) | Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina. |